Page 202 - Drug Class Review
P. 202

Page 131 of 205
             Drug Effectiveness Review Project










                                                  To evaluate the efficiency of donepezil treatment in early stage Alzheimer’s Disease



















                                                                  placebo   N/A   24 weeks   57  Generally healthy ambulatory patients aged 50-92 years; diagnosis of probable AD within the past 12  months; modified Hachinski Ischemia Scale score of 4 or less; Global Dementia Rating score of 0.5 or  1.0; MMSE score of 21-26; mild impairment in activities of daily living  If memory decline was possibly attributable to a psychiatric or neurologic disorder or to cognitive deficits  following head trauma; previous treatment with cholinesterase inhibitors
























                          Alzheimer Drugs      Authors:  Seltzer et al. 46     Year:  2004   Country: US   Eisai Inc. and Pfizer Inc.      Study design: RCT  Setting: Multi-center (17 sites)   Sample size: 153   donepezil   5-10 mg/d   24 weeks   96               NR



























             Final Report Update 1     Efficacy/Effectiveness      STUDY:      FUNDING:   RESEARCH OBJECTIVE:      DESIGN:           INTERVENTION:    Dose:     Duration:     Sample size:   INCLUSION:   EXCLUSION:   OTHER MEDICATIONS/  INTERVENTIONS ALLOWED:     Alzheimer's Drugs
   197   198   199   200   201   202   203   204   205   206   207